Opus Genetics to Participate in Upcoming Investment Conferences

(NASDAQ:IRD), RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences. BTIG 5th Annual […]

Valitor Announces Upcoming Presentation at the 15th Annual Ophthalmology Innovation Summit (OIS)

BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present preclinical data highlighting the potential of VLTR-559, a long-acting anti-VEGF biologic designed to enable twice-yearly dosing for the treatment of wet age-related macular degeneration (AMD),

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV(TM)) Clinical Results

(NASDAQ:HUMA), – Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated

4DMT to Participate in 8th Annual Evercore Healthcare Conference

(NASDAQ:FDMT), EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the 8th Annual Evercore

Gentex and Genie Partner to Bring Cloud-Based Garage Door Activation to HomeLink

(NASDAQ:GNTX), ZEELAND, Mich. and MT. HOPE, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX) and The Genie(R) Company today announced an agreement that allows Gentex to integrate Genie's Aladdin Connect(R) platform into HomeLink(R), the automotive industry's leading car-to-home automation system. The partnership will enable Gentex customers to control connected Genie products via

Curacao Unveils Its Biggest Black Friday Weekend Ever with Doorbusters and Club-Exclusive Savings

LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) — Curacao, one of the largest Hispanic-focused retailers on the West Coast, is closing out its monthlong savings celebration with the main event: the 2025 Black Friday Weekend Sale, running Thursday, November 27 through Sunday, November 30. Shoppers can take advantage of four days of major savings with

EBZT Reserves Nasdaq Ticker “APES” as Part of Its Planned Uplisting Strategy

(PinkSheets:EBZT),(Pinksheets:EBZT), Jacksonville, Florida, Nov. 20, 2025 (GLOBE NEWSWIRE) — Everything Blockchain (OTC: EBZT), a public AI development lab for digital asset markets, today announced that it has reserved the Nasdaq ticker symbol “APES.” Management believes “APES” is a rare, culture-heavy ticker that fits perfectly for a blockchain, iGaming, and prediction markets company. Leadership sees it

Shattuck Labs to Participate in Upcoming December Investor Conferences

(NASDAQ:STTK), AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

(NASDAQ:FBLG), HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has received both public and private Human Research Ethics

Scroll to Top